EMPLOYMENT AGREEMENTEmployment Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • Massachusetts
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of this 8th day of May, 2007, by and between Targanta Therapeutics Corporation, (the “Company”), and Dr. Thomas R. Parr (“Employee”) (collectively, the “Parties”).
TARGANTA THERAPEUTICS CORPORATION OPTION AGREEMENTStock Option Plan • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • Delaware
LICENSE AGREEMENTLicense Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is made effective and entered into as of December 23, 2005 (the “Effective Date”), by and between InterMune, Inc. (“Licensee”), a corporation organized and existing under the laws of the State of Delaware, and Eli Lilly and Company (“Lilly”), a corporation organized and existing under the laws of the State of Indiana. Licensee and Lilly are sometimes referred to herein individually as a “Party” and collectively as “Parties.” For certain purposes under this Agreement, InterMune, Inc. is sometimes referred to as “InterMune.”
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • New York
* Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
TARGANTA THERAPEUTICS CORPORATION OPTION AGREEMENT FOR QUÉBEC EMPLOYEESOption Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • Delaware
ContractTarganta Therapeutics Corp. • June 27th, 2007 • Pharmaceutical preparations
[*] = CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
AMENDMENT NUMBER 4 TO THE DEVELOPMENT AND SUPPLY AGREEMENT DATED DECEMBER 28, 2001 BETWEEN ABBOTT LABORATORIES AND INTERMUNE, INC. (TARGANTA THERAPEUTICS)Development and Supply Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • New York
This Fourth Amendment, to the Development and Supply Agreement dated as of December 28, 2001, as amended by Amendment Number 1 dated April 26, 2002, Amendment Number 2 dated October 15, 2002, and Amendment Number 3 dated December 22, 2005 (the “Agreement”), is effective as of December 15, 2006 (“Amendment Effective Date”), between Abbott Laboratories, an Illinois corporation (“Abbott”), and Targanta Therapeutics Corporation, an Indianapolis, Indiana corporation (“Targanta”) as purchaser of all rights title and interest related to Oritavancin from InterMune, Inc., a Delaware corporation (“InterMune”). Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement.
AMENDMENT NUMBER 3 TO DEVELOPMENT AND SUPPLY AGREEMENT DATED DECEMBER 28, 2001 BETWEEN ABBOTT LABORATORIES AND INTERMUNE, INC.Development and Supply Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • New York
This Amendment No. 3, to the Development and Supply Agreement dated as of December 28, 2001, as amended by Amendment No. 1 dated April 26, 2002, Amendment No. 2 dated October 15, 2002, and the letter agreement regarding “Authorization for Disclosure of Confidential Information” dated July 18, 2003 (collectively, the “Agreement”), is effective as of December 22, 2005 (“Amendment No. 3 Effective Date”) between Abbott Laboratories, an Illinois corporation (“Abbott”), and InterMune, Inc., a Delaware corporation (“InterMune”). Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement.
MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • Ohio
This MANUFACTURING SERVICES AGREEMENT (“Agreement”) is made this 27th day of March, 2007, by and between Cardinal Health PTS, LLC, having a place of business at 4401 Alexander Blvd NE, Albuquerque, NM 87107 (“Cardinal Health”) and Targanta Therapeutics, Corp. (“Targanta”), having its principal place of business at 225 South East Street, Suite 390, Indianapolis, IN 46202.
LEASE - Multi-Tenant Building - BETWEEN SOCIÉTÉ IMMOBILÌRE TECHNOLOGIQUE DE MONTRÉAL INC. AS LANDLORD AND PHAGETECH INC. AS TENANTLease Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • Quebec
WHEREAS the Landlord has agreed to lease to the Tenant and the Tenant has agreed to lease from the Landlord upon the terms and conditions herein contained, certain premises forming part of a building located in Phase 2 of the Technoparc Saint-Laurent, in the City of Saint-Laurent, Province of Quebec.
ContractTarganta Therapeutics Corp. • June 27th, 2007 • Pharmaceutical preparations
[*] = CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
OFFICE SUBLEASE AGREEMENTOffice Sublease Agreement • June 27th, 2007 • Targanta Therapeutics Corp. • Pharmaceutical preparations • Indiana
THIS OFFICE SUBLEASE AGREEMENT (the “Lease”) is executed as of this 1st day of March, 2007, by and between UNITED FARM FAMILY LIFE INSURANCE COMPANY (“UFFLIC”), an Indiana corporation, and UNITED FARM FAMILY MUTUAL INSURANCE COMPANY (“UFMIC”), an Indiana corporation (UFFLIC and UFFMIC jointly shall be referred to hereinafter as “Lessor”), and TARGANTA THERAPEUTICS CORPORATION, a Delaware corporation (hereinafter referred to as “Lessee”), and Lessee does hereby lease from Lessor the following described premises upon the terms and conditions hereinafter set forth.
